Twist Bioscience Beheer
Beheer criteriumcontroles 2/4
De CEO Twist Bioscience is Emily Leproust, benoemd in Apr2013, heeft een ambtstermijn van 13.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.78M, bestaande uit 5.2% salaris en 94.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.66% van de aandelen van het bedrijf, ter waarde $ 52.61M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 8.9 jaar.
Belangrijke informatie
Emily Leproust
Algemeen directeur
US$13.8m
Totale compensatie
| Percentage CEO-salaris | 5.22% |
| Dienstverband CEO | 13.4yrs |
| Eigendom CEO | 0.7% |
| Management gemiddelde ambtstermijn | 3.3yrs |
| Gemiddelde ambtstermijn bestuur | 8.9yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Sep 03
TWST: AI Drug Discovery Hype Will Likely Outrun 2026 Execution Reality
Analysts have raised the fair value estimate for Twist Bioscience from $38.04 to $57.50, citing a series of higher Street price targets clustered around $95 to $120. These targets are linked to updated models following Q3 results and growing expectations for revenue contributions from AI-enabled drug discovery.Seeking Alpha • Aug 20
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)
Summary Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist. TWST stock's upside hinges on future AI-driven healthcare markets, but near-term volatility and speculative sentiment dominate the investment case. Read the full article on Seeking Alpha
Narratiefupdate • Aug 13
TWST: AI Order Momentum Will Test Sustainability After Equity Raise
Analysts have lifted the Twist Bioscience fair value estimate from $92.50 to $105.30, citing refreshed models that reflect updated revenue expectations, AI-enabled drug discovery order trends, and revised sector assumptions across recent research. Analyst Commentary Recent Street research around Twist Bioscience shows a cluster of higher fair value targets and mostly positive views on execution, with one more cautious voice highlighting valuation risks after a strong share price run.Analyse-artikel • Aug 06
Earnings Update: Here's Why Analysts Just Lifted Their Twist Bioscience Corporation (NASDAQ:TWST) Price Target To US$104
Shareholders will be ecstatic, with their stake up 35% over the past week following Twist Bioscience Corporation 's...Narratiefupdate • Jul 30
TWST: AI Drug Discovery Hopes Face Sector And Execution Headwinds
The updated analyst price target for Twist Bioscience moves from $71.10 to $92.50 as analysts refresh models around higher assumed revenue growth, a lower discount rate, and a higher future P/E multiple, partly offset by more conservative profit margin expectations. Analyst Commentary Recent Street research on Twist Bioscience points to an active debate on valuation and execution as the stock responds to shifting expectations around growth, margins, and the broader life science tools sector.
Narratiefupdate • Jul 16
TWST: AI Drug Discovery Demand Will Shape Multi Year Upside Potential
Analysts have raised the fair value estimate for Twist Bioscience to $120 from $95, reflecting updated models that incorporate slightly higher revenue growth assumptions, adjusted profit margin expectations, and a higher future P/E, in line with a series of recent price target increases across the Street. Analyst Commentary Bullish analysts covering Twist Bioscience have been revisiting their models, with a series of higher price targets and positive views on the company’s execution in life science tools and synthetic biology.Narratiefupdate • Jul 02
TWST: AI Drug Discovery Exposure And Tools Recovery Will Shape Multi Year Outlook
The analyst fair value estimate for Twist Bioscience has been revised from $58.00 to $95.00. This change reflects updated sector views and recent price target increases across the Street.Analyse-artikel • Jun 18
Twist Bioscience (TWST) Stock Looks 42.9% Overvalued After Bullish Analyst Calls
Recent bullish coverage from firms such as Canaccord Genuity, highlighting Twist Bioscience (TWST) silicon-based lab-on-a-chip platform and AI-enabled drug discovery efforts, has pushed Twist Bioscience stock firmly into focus for many investors. See our latest analysis for Twist Bioscience. That bullish research comes after a sharp move in the Twist Bioscience share price. The stock closed at US$82.87, with a 30 day share price return of 66.44% and a 1 year total shareholder return of...Narratiefupdate • Jun 18
TWST: AI Drug Discovery Hopes Will Be Tested By Sector Headwinds
The analyst fair value estimate for Twist Bioscience has been lifted from $64.38 to $71.10. Analysts point to a higher assumed revenue growth rate, a richer future P/E and sector research that highlights the company’s growing role in next generation drug discovery and development as key factors in the new price target.Narratiefupdate • Jun 04
TWST: AI Drug Discovery Hopes Will Outrun Earnings Execution Risk
The analyst price target for Twist Bioscience has been revised higher to $64.38 from $63.33. Analysts point to updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E as key drivers of the change.Narratiefupdate • May 20
TWST: Silicon DNA Platform And Profitability Shift Will Drive Bullish Repricing
Analysts have raised their average price target for Twist Bioscience to about $63.33 from $55.00, citing updated assumptions around profitability, modest tweaks to discount rates and growth, and a lower future P/E multiple as key inputs in their models. Analyst Commentary Recent research on Twist Bioscience centers on how updated profitability assumptions and valuation frameworks translate into higher price targets, with several analysts revising their models over a short period.Narratiefupdate • Apr 29
TWST: Silicon DNA Platform And Expanded Partnerships Will Shape Balanced Risk Reward Profile
Twist Bioscience's analyst fair value estimate has been reset from $35.63 to $55.00. Analysts point to a series of recent price target increases from firms such as Barclays, Evercore ISI, Guggenheim and Baird as support for the higher range.Narratiefupdate • Apr 15
TWST: Bispecific Platform Deal And Tools Recovery Will Shape Multi Year Outlook
Twist Bioscience's updated analyst price target remains at $58.00. Recent Street research cites revised assumptions around revenue growth, profitability, and a lower future P/E as key drivers behind the refreshed narrative.Narratiefupdate • Mar 30
TWST: Sector Recovery Hopes Will Likely Outpace 2026 Execution Reality
Analysts have lifted the implied fair value estimate for Twist Bioscience by about $5 to roughly $38 per share, citing refreshed models that incorporate updated 2026 frameworks, recovering end markets and multiple avenues for growth reflected in recent price target increases from firms across the diagnostic tools peer group. Analyst Commentary Recent Street research on Twist Bioscience has centered on refreshed 2026 frameworks, sector rotation within diagnostic tools and how quickly end markets are recovering.Narratiefupdate • Mar 16
TWST: 2026 Tools Recovery And Bispecific Deal Will Support Multi Year Upside
Analysts have raised their average price targets on Twist Bioscience by double digit dollar amounts. Firms such as Baird, Evercore ISI, Barclays, Guggenheim and TD Cowen have cited recovering end markets, improving sentiment into 2026 and multiple avenues for upside to previously derisked growth assumptions.Narratiefupdate • Mar 02
TWST: 2026 Tools Recovery Framework Will Drive Multi Year Platform Upside
Analysts have lifted their price targets on Twist Bioscience by $8 to $17 per share in recent research, tying the changes to improving tools sector sentiment, recovering end markets into 2026, and what they view as multiple avenues for upside within a clearer multi year growth framework. Analyst Commentary Bullish analysts are clustering around a more constructive view on Twist Bioscience, pointing to a clearer multi year growth framework and a tools sector that they see as recovering into 2026.Narratiefupdate • Feb 16
TWST: Multi Year Tools Framework Will Drive DNA Synthesis Platform Upside
Analysts have raised their price targets for Twist Bioscience, supporting a fair value move from $42.00 to $58.00. They cite a clearer multi year growth framework, recovering end markets, and a tools focused setup into 2026.Narratiefupdate • Feb 02
TWST: Sector Recovery Optimism Will Likely Outrun Synthetic Biology Market Realities
Analysts have lifted their price targets on Twist Bioscience by up to about $10, citing improving sentiment into 2026, recovering end markets, and what they see as multiple potential avenues for growth in the tools and synthetic biology businesses, despite some remaining questions on market size. Analyst Commentary Recent research commentary has generally leaned constructive on Twist Bioscience, with several firms lifting their price targets and pointing to tools and synthetic biology as potential growth drivers into 2026.Narratiefupdate • Jan 19
TWST: Sector Recovery Hopes Will Likely Overstate Synthetic Biology Upside
Analysts have raised their fair value estimate for Twist Bioscience to $33 from $25, citing higher assumed revenue growth, improved profit margins, and future P/E multiples supported by recent price target increases and commentary regarding sector recovery, multi-year growth frameworks, and share gains in DNA synthesis. Analyst Commentary Recent Street research on Twist Bioscience reflects a mix of optimism and restraint, with several firms revisiting their price targets and highlighting both potential upside drivers and key execution questions.Analyse-artikel • Jan 14
Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 30%
The Twist Bioscience Corporation ( NASDAQ:TWST ) share price has done very well over the last month, posting an...Narratiefupdate • Jan 05
TWST: Commercial Execution Will Drive DNA Synthesis Platform Toward Profitable Scale
Analysts have trimmed their price target on Twist Bioscience from $50 to $42 per share. This reflects a slightly higher discount rate and more tempered revenue growth expectations, even as they acknowledge the company’s differentiated DNA synthesis platform, cost leadership, and continued market share gains.Narratiefupdate • Dec 15
TWST: Silicon DNA Platform And Aggressive Commercial Push Will Drive Share Gains
Analysts have modestly trimmed their price target on Twist Bioscience by a few dollars per share to better reflect lingering questions around the size and timing of synthetic biology opportunities, even as they highlight the company’s differentiated, cost advantaged DNA synthesis platform and ongoing share gains as key drivers of long term upside. Analyst Commentary Bullish analysts emphasize that Twist’s differentiated, technology driven DNA synthesis platform, built on proprietary silicon chip technology, underpins a durable competitive moat that can support premium growth and multiple expansion over time.Narratiefupdate • Dec 01
TWST: Silicon Chip DNA Platform Will Drive Continued Market Share Gains
Analysts have slightly raised their fair value estimate for Twist Bioscience to $35.63 from $35.57 per share. They cite ongoing market share gains and commercial momentum, even as questions remain about future growth opportunities.Narratiefupdate • Nov 17
TWST: Silicon Chip Technology Will Drive Future Market Share Gains
Analysts have lowered their price target for Twist Bioscience from $39.43 to $35.57, citing stable yet competitive end markets, slightly reduced growth expectations, and a longer path to profitability. Analyst Commentary Recent research from the Street highlights a mix of optimism and caution in outlooks for Twist Bioscience.Narratiefupdate • Nov 01
TWST: Share Valuations Will Stabilize As End Markets Remain Strong
Analysts have lowered their price target for Twist Bioscience to $40 from $45, citing stable end markets and improved sentiment as share valuations adjust. Analyst Commentary Bullish Takeaways Bullish analysts highlight that end markets remain stable, which supports reliable performance in the near term.Narratiefupdate • Oct 18
SynBio And NGS Demand Will Broaden Global Market Reach
Analysts have revised Twist Bioscience’s price target downward from $40.00 to $39.43, citing stable end markets and expectations of improving sentiment as the primary rationale for the modest adjustment. Analyst Commentary Recent analyst updates on Twist Bioscience reflect a nuanced perspective on the company’s outlook, highlighting both potential opportunities and ongoing challenges that could influence near-term valuation and long-term growth prospects.Analyse-artikel • Oct 09
Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 31%
Those holding Twist Bioscience Corporation ( NASDAQ:TWST ) shares would be relieved that the share price has rebounded...Narratiefupdate • Oct 04
SynBio And NGS Demand Will Broaden Global Market Reach
Analysts have lowered their price target for Twist Bioscience from $42.14 to $40.00. They cite stable end markets and a cautiously optimistic outlook based on current valuations and improved profit margin expectations.Narratiefupdate • Sep 19
SynBio And NGS Demand Will Broaden Global Market Reach
Twist Bioscience’s consensus price target increased to $42.14, as a higher future P/E suggests elevated growth expectations despite a decline in net profit margin. What's in the News Collaborated with Synthetic Design Lab, utilizing proprietary tools to support SDL's research activities.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$137m |
| Mar 31 2026 | n/a | n/a | -US$81m |
| Dec 31 2025 | n/a | n/a | -US$77m |
| Sep 30 2025 | US$14m | US$720k | -US$78m |
| Jun 30 2025 | n/a | n/a | -US$85m |
| Mar 31 2025 | n/a | n/a | -US$191m |
| Dec 31 2024 | n/a | n/a | -US$197m |
| Sep 30 2024 | US$8m | US$685k | -US$209m |
| Jun 30 2024 | n/a | n/a | -US$220m |
| Mar 31 2024 | n/a | n/a | -US$192m |
| Dec 31 2023 | n/a | n/a | -US$206m |
| Sep 30 2023 | US$8m | US$685k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$209m |
| Mar 31 2023 | n/a | n/a | -US$213m |
| Dec 31 2022 | n/a | n/a | -US$214m |
| Sep 30 2022 | US$6m | US$665k | -US$218m |
| Jun 30 2022 | n/a | n/a | -US$208m |
| Mar 31 2022 | n/a | n/a | -US$188m |
| Dec 31 2021 | n/a | n/a | -US$165m |
| Sep 30 2021 | US$1m | US$590k | -US$152m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$123m |
| Dec 31 2020 | n/a | n/a | -US$117m |
| Sep 30 2020 | US$7m | US$519k | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$147m |
| Mar 31 2020 | n/a | n/a | -US$147m |
| Dec 31 2019 | n/a | n/a | -US$141m |
| Sep 30 2019 | US$8m | US$477k | -US$108m |
Compensatie versus markt: De totale vergoeding ($USD 13.78M ) Emily } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.42M ).
Compensatie versus inkomsten: De vergoeding van Emily is gestegen terwijl het bedrijf verliesgevend is.
CEO
Emily Leproust (53 yo)
13.4yrs
Tenure
US$13,781,570
Compensatie
Dr. Emily Marine Leproust, Ph D., is Director of GeneDx, Inc. from July 2021. Dr. Leproust was Director of Atlas Data Storage, Inc. since May 2025.Dr. Leproust serves as Independent Director at CM Life Sc...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 13.4yrs | US$13.78m | 0.66% $ 52.6m | |
| President & COO | 3.9yrs | US$8.02m | 0.073% $ 5.8m | |
| Chief Financial Officer | 2.7yrs | US$4.22m | 0.038% $ 3.1m | |
| Chief Legal Officer & Corporate Secretary | 5yrs | US$3.62m | 0.014% $ 1.1m | |
| Senior Vice President of Human Resources | 10.5yrs | US$3.35m | 0.19% $ 15.1m | |
| VP & Chief Accounting Officer | 3.3yrs | geen gegevens | 0.021% $ 1.7m | |
| Chief Technology Officer | 5.6yrs | geen gegevens | geen gegevens | |
| Chief Information Officer | 1.9yrs | geen gegevens | geen gegevens | |
| Chief Scientific Officer | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Sales & Support | 1.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Product & Marketing | less than a year | geen gegevens | geen gegevens | |
| Chief Corporate Responsibility Officer & Senior VP of Corporate Affairs | 1.6yrs | geen gegevens | geen gegevens |
3.3yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TWST wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 13.4yrs | US$13.78m | 0.66% $ 52.6m | |
| Independent Director | 12.9yrs | US$299.97k | 0.17% $ 13.3m | |
| Lead Independent Director | 12.2yrs | US$337.47k | 0.10% $ 8.1m | |
| Independent Director | 7.3yrs | US$312.47k | 0.045% $ 3.6m | |
| Independent Director | 9.8yrs | US$304.97k | 0.038% $ 3.1m | |
| Independent Director | 7.9yrs | US$313.72k | 0.020% $ 1.6m | |
| Independent Director | 1.1yrs | US$404.00k | 0.027% $ 2.2m | |
| Independent Director | 5.1yrs | US$304.97k | 0.027% $ 2.2m |
8.9yrs
Gemiddelde duur
65.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TWST wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.9 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/09 21:25 |
| Aandelenkoers aan het einde van de dag | 2026/09/09 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/09/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Twist Bioscience Corporation wordt gevolgd door 16 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |